Therapeutic potential of fractalkine: a novel approach to metastatic colon cancer

Fractalkine is involved in the pathogenesis of different types of cancer and in various clinical disease states Several experimental approaches have shown that a variety of chemokines have anti-tumour activity either by chemoattracting natural killer cells, monocytes and macrophages, or by accumulating dendritic cells.1 Accumulating evidence has shown that fractalkine (CX3CL1), the unique member of the CX3C chemokine subfamily, is involved in the pathogenesis of different types of cancer2,3 and in various clinical disease states beyond cancer, such as atherosclerosis, glomerulonephritis, rheumatoid arthritis, HIV disease and sepsis.4–6 In contrast with other chemokines, fractalkine exists in two forms, each mediating distinct biological actions.7 The membrane-anchored protein, which is expressed primarily on the endothelium, serves as an adhesion protein promoting the retention of monocytes and T cells.8 The soluble form originates from extracellular proteolysis by proteases, such as tumour necrosis factor-α converting enzyme (also known as ADAM17) and ADAM10.9 The secreted form resembles more a conventional chemokine and strongly induces chemotaxis and causes migration of natural killer cells, cytotoxic T lymphocytes and macrophages. Both chemotaxis and adhesion are mediated by the G protein-coupled receptor CX3CR1,10 which is present on natural killer cells, CD14+ monocytes and on some subpopulations of T cells. In a variety of pathological conditions, fractalkine …

[1]  B. Cambien,et al.  Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer , 2006, Gut.

[2]  H. Mizuguchi,et al.  Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors , 2006, European journal of immunology.

[3]  O. Quehenberger,et al.  Expression of Fractalkine (CX3CL1) and its Receptor, CX3CR1, Is Elevated in Coronary Artery Disease and Is Reduced During Statin Therapy , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[4]  Taoyong Chen,et al.  Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. , 2003, Immunology Letters.

[5]  C. Blobel,et al.  Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). , 2001, The Journal of biological chemistry.

[6]  A. Foussat,et al.  Deregulation of the expression of the fractalkine/fractalkine receptor complex in HIV-1-infected patients. , 2001, Blood.

[7]  D. C. Woodruff,et al.  Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. , 2001, Arthritis and rheumatism.

[8]  D. Patel,et al.  A Role for Fractalkine and Its Receptor (CX3CR1) in Cardiac Allograft Rejection1 , 2000, The Journal of Immunology.

[9]  A. Yamauchi,et al.  Fractalkine-Mediated Endothelial Cell Injury by NK Cells1 , 2000, The Journal of Immunology.

[10]  E. Génin,et al.  Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. , 2000, Science.

[11]  Y. Xia,et al.  Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. , 1999, Kidney international.

[12]  D. Patel,et al.  Fractalkine and CX3CR1 Mediate a Novel Mechanism of Leukocyte Capture, Firm Adhesion, and Activation under Physiologic Flow , 1998, The Journal of experimental medicine.

[13]  D. Lo,et al.  In Vivo Inhibition of CC and CX3C Chemokine–induced Leukocyte Infiltration and Attenuation of Glomerulonephritis in Wistar-Kyoto (WKY) Rats by vMIP-II , 1998, The Journal of experimental medicine.

[14]  T. Schall,et al.  Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion , 1997, Cell.

[15]  Wei Wang,et al.  A new class of membrane-bound chemokine with a CX3C motif , 1997, Nature.

[16]  F. Tanaka,et al.  The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. , 2005, International journal of oncology.

[17]  P. Allavena,et al.  Chemokines and chemokine receptors during activation and deactivation of monocytes and dendritic cells and in amplification of Th1 versus Th2 responses , 1998, International journal of clinical & laboratory research.